Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
ABM-1310 inhibits BRAF V600, including BRAF V600E, potentially leading to inhibition of tumor growth (Cancer Res (2020) 80 (16_Supplement): 4038).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ABM-1310||ABM1310|ABM 1310||BRAF Inhibitor 24||ABM-1310 inhibits BRAF V600, including BRAF V600E, potentially leading to inhibition of tumor growth (Cancer Res (2020) 80 (16_Supplement): 4038).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600X||Advanced Solid Tumor||predicted - sensitive||ABM-1310||Phase I||Actionable||In a Phase I trial, ABM-1310 treatment was tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors harboring BRAF V600X, resulting in 2 partial responses (1 pleomorphic xanthroastrocytoma, 1 glioblastoma) and 8 stable diseases among 16 evaluable patients (J Clin Oncol 41, 2023 (suppl 16; abstr 3098); NCT04190628).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04190628||Phase I||ABM-1310 ABM-1310 + Cobimetinib||Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors||Recruiting||USA||0|